Early manifestation and progressive multicomponent current of McCune–Albright-Braitsev syndrome in a girl 9 years old: a clinical case and literature review

McCune–Albright–Braitsev Syndrome (MAB syndrome) is a very rare multisystem disease manifested by fibrous bone dysplasia, coffee-and-milk colored spots, hyperfunction of various endocrine glands and a number of pathologies of other body systems. We present a description of a clinical case of a severe progressive course of MAB Syndrome in a nine-year-old girl. With this diagnosis, the girl is observation of the girl began when she was 2.5 years old, when spots of coffee-and-milk, polyosseous fibrous dysplasia, peripheral premature sexual development against a backdrop of estrogen-­secreting ovarian cysts, multinodular goiter were detected. In the process of dynamic observation, it was noted that the child’s active growth stopped against a backdrop of deformities of the skeletal system with multiple repeated fractures of the extremities; progression of skull deformity with stenosis of the optic nerve canals and deterioration of visual acuity; development of STH hypersecretion, hypophosphatemic rickets, tachycardia. Appropriate suppressive / replacement therapy was prescribed for each of the endocrine dysfunctions. The article presents algorithms for examining a girl in dynamics, criteria for choosing a component-wise management tactics and a discussion of the features of the course of all manifestations of the Syndrome.

1. McCune DJ, Bruch H. Osteodystrophia fibrosa: Report of a case in which the condition was combined with precocious puberty, pathologic pigmentation of the skin and hyperthyroidism, with a review of the literature. Am. J. Dis. Child. 1937;54(4):806-848. doi: https://doi.org/10.1001/archpedi.1937.01980040110009

2. Albright F, Scoville B, Sulkowitch HW. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation, and a gonadal dysfunction further observations including the report of two more cases. Endocrinology. 1937;216(17):727-746. doi: https://doi.org/10.1210/endo-22-4-411

3. Braytcev BR. Osteodystrophia fibrosa localisata. Leningrad: Vestnik hirurgii i pogranichnih oblastey; 1928. P. 301-315 (In Russ.).

4. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3(1):12. doi: https://doi.org/10.1186/1750-1172-3-12

5. Weinstein LS, Shenker A, Gejman PV, et al. Activating Mutations of the Stimulatory G Protein in the McCune–Albright Syndrome. N Engl J Med. 1991;325(24):1688-1695. doi: https://doi.org/10.1056/NEJM199112123252403

6. Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J. Rare Dis. 2012;7(1):1-14. doi: https://doi.org/10.1186/1750-1172-7-s1-s4

7. Wood LD, Noë M, Hackeng W, et al. Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Arch. 2017;470(4):391-400. doi: https://doi.org/10.1007/s00428-017-2086-2

8. Satomura Y, Bessho K, Kitaoka T, et al. Neonatal cholestasis can be the first symptom of McCune–Albright syndrome: A case report. World J Clin Pediatr. 2021;10(2):7-14. doi: https://doi.org/10.5409/wjcp.v10.i2.7

9. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin. Genet. 1986;29(4):321-324. doi: https://doi.org/10.1111/j.1399-0004.1986.tb01261.x

10. Boyce AM, Glover M, Kelly MH, et al. Optic Neuropathy in McCune-Albright Syndrome: Effects of Early Diagnosis and Treatment of Growth Hormone Excess. J Clin Endocrinol Metab. 2013;98(1):E126-E134. doi: https://doi.org/10.1210/jc.2012-2111

11. Yoshimoto M, Nakayama M, Baba T, et al. A Case of Neonatal McCune-Albright Syndrome with Cushing Syndrome and Hyperthyroidism. Acta Paediatr. 1991;80(10):984-987. doi: https://doi.org/10.1111/j.1651-2227.1991.tb11769.x

12. Lourenço R, Dias P, Gouveia R, et al. Neonatal McCune-Albright syndrome with systemic involvement: A case report. J Med Case Rep. 2015;9. doi: https://doi.org/10.1186/s13256-015-0689-2

13. Schulz E, Klohs S, Königs I, et al. Case Report: Neonatal McCune-Albright Syndrome with Juvenile Ovarian Granulosa Cell Tumor in a 4 Months Old Girl. European Society for Paediatric Endocrinology. 2018.

14. Rol narusheniy postreciptornogo signala v razvitii multigormonalnoy rezistentnosti i avtonomnoy giperfunkcii endokrinnih zhelez u detey. FGBU «NMIC endokrinologii» (In Russ.). [Internet]. Av. at:: https://www.endocrincentr.ru/specialists/science/dissertacionnyy-sovet/dissertacii/rol-narusheniy-postreceptornogo-signalinga-v-razvitii-multigormonalnoy. Link active on 29.03.2021.

15. Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis. 2019;14(1):139. doi: https://doi.org/10.1186/s13023-019-1102-9

16. Hart ES, Kelly MH, Brillante B, et al. Onset, Progression, and Plateau of Skeletal Lesions in Fibrous Dysplasia and the Relationship to Functional Outcome. J Bone Miner Res. 2007;22(9):1468-1474. doi: https://doi.org/10.1359/jbmr.070511

17. Grob F, Clark J, Zacharin M. Severe Fibrous Dysplasia in McCune-Albright Syndrome: A Need for Continuous Surveillance. Horm. Res. Paediatr. 2020;93(6):402-408. doi: https://doi.org/10.1159/000511752

18. Amit M, Collins MT, FitzGibbon EJ, et al. Surgery versus Watchful Waiting in Patients with Craniofacial Fibrous Dysplasia – a Meta-Analysis. PLoS One. 2011;6(9):e25179. doi: https://doi.org/10.1371/journal.pone.0025179

19. Lee J, FitzGibbon E, Chen Y, et al. Clinical guidelines for the management of craniofacial fibrous dysplasia. Orphanet J Rare Dis. 2012;7(S1):S2. doi: https://doi.org/10.1186/1750-1172-7-S1-S2

20. Feuillan P, Calis K, Hill S, et al. Letrozole Treatment of Precocious Puberty in Girls with the McCune-Albright Syndrome: A Pilot Study. J Clin Endocrinol Metab. 2007;92(6):2100-2106. doi: https://doi.org/10.1210/jc.2006-2350

21. Michael H, Härkönen PL, Kangas L, et al. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol. 2007;151(3):384-395. doi: https://doi.org/10.1038/sj.bjp.0707232

22. Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003;143(1):60-66. doi: https://doi.org/10.1016/S0022-3476(03)00128-8

23. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). Oncol Lett. 2015;9(4):1495-1501. doi: https://doi.org/10.3892/ol.2015.2962

24. Sims EK, Garnett S, Guzman F, et al. Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome. Int J Pediatr Endocrinol. 2012;2012(1):26. doi: https://doi.org/10.1186/1687-9856-2012-26

25. Lavoué V, Morcel K, Bouchard P, et al. Restoration of ovulation after unilateral ovariectomy in a woman with McCune–Albright syndrome: a case report. Eur J Endocrinol. 2008;158(1):131-134. doi: https://doi.org/10.1530/EJE-07-0482

26. Frantz AG, Rabkin MT. Effects of Estrogen and Sex Difference on Secretion of Human Growth Hormone1. J Clin Endocrinol Metab. 1965;25(11):1470-1480. doi: https://doi.org/10.1210/jcem-25-11-1470

27. Ross JL, Pescovitz OH, Barnes K, et al. Growth hormone secretory dynamics in children with precocious puberty. J Pediatr. 1987;110(3):369-372. doi: https://doi.org/10.1016/S0022-3476(87)80496-1

28. Cutler CM, Lee JS, Butman JA, et al. Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. Neurosurgery. 2006;59(5):1011-1017. doi: https://doi.org/10.1227/01.neu.0000254440.02736.e3

29. Leet AI, Chebli C, Kushner H, et al. Fracture Incidence in Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome. J Bone Miner Res. 2003;19(4):571-577. doi: https://doi.org/10.1359/JBMR.0301262

30. Berglund JA, Tella SH, Tuthill KF, et al. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates. J Bone Miner Res. 2018;33(9):1641-1648. doi: https://doi.org/10.1002/jbmr.3446

31. Soldin SJ et al. Pediatric reference ranges for phosphate on the Hitachi 747 analyzer // Clin. Chem. 1997; 43:S198. (Abstract).

32. Soldin SJ, Hunt C, Hicks JM. Pediatric reference ranges for Phosphorus on the Vitros 500 Analyzer. Clin Chem. 1999;45:A22.

33. Lockitch G, Halstead AC, Albersheim S, et al. Age- and sex-specific pediatric reference intervals for biochemistry analytes as measured with the Ektachem-700 analyzer. Clin Chem. 1988;34(8):1622-1625. doi: https://doi.org/10.1093/clinchem/34.8.1622

34. Payne RB. Renal Tubular Reabsorption of Phosphate (TmP/GFR): Indications and Interpretation. Ann Clin Biochem Int J Lab Med. 1998;35(2):201-206. doi: https://doi.org/10.1177/000456329803500203